Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels

Specific inhibitor of factor Xa

Novel K(ATP) channel opener

Novel inhibitor of urate transporter 1 (URAT1)

Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist

Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha

Novel RORγ

Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway

Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway

Novel antitubercular agent, inhibiting InhA and FAS-II pathway

Novel specific inhibitor of Fusarium myosin I; Fungicide

Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor

Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC)

Non-toxic anti-relapse agent, acamprosate

Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs)

Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner

Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth

Selective DGAT2 inhibitor

Selective DGAT1 inhibitor

Novel TARP γ-8 Selective AMPAR Negative Modulator

Negative control for JNJ-54119936

Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion

Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2)

Novel inhibitor of PDE10A

Novel potent, orally active LTA4H inhibitor

Negaive control for JNJ-42396302

Negative control for JNJ-40068782

Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease

Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors